Physician profile
Brian Defade
NPI 1679764534
$3,903.20
in general payments reported to CMS, 2019-2025
17 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,591 · 2020: $68.15 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $2,689.34 | 2019 | |
| Boston Scientific Corporation | $482.61 | 2019 | |
| Astellas Pharma US INC | $226.96 | 2019-2025 | Xtandi |
| Ferring Pharmaceuticals INC. | $62.38 | 2019-2020 | |
| Procept Biorobotics Corporation | $60.22 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $50.24 | 2025 | Orgovyx, Gemtesa |
| 180 Medical, INC. | $49.46 | 2019 | |
| Pfizer INC. | $43.63 | 2019-2020 | |
| Coloplast Corp | $41.29 | 2019 | |
| Dendreon Pharmaceuticals LLC | $33.21 | 2025 | Provenge |
| Olympus America INC. | $31.34 | 2025 | Itind System |
| Endo Pharmaceuticals INC. | $30.15 | 2020 | |
| Endo USA, INC. | $26.31 | 2025 | Aveed, Xiaflex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.47 | 2025 | Lifevest |
| Edwards Lifesciences Corporation | $22.45 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $18.60 | 2025 | |
| Allergan, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Defade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.